CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $267.44M, lower than 95% of all stocks globally
- PositionReturn on equity is -986.3%, lower than 95% of its Biotechnology peers (median -22.3%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
267.44MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.46xvs all stocks
52-Week Change
79.33%vs all stocks
Market Capitalization
267.44MUSDvs all stocks (USD)
Enterprise Value
258.56MUSDvs all stocks (USD)
Forward P/E
-22.22xvs Biotechnology peers
Price to Book (MRQ)
85.94xvs Biotechnology peers
Enterprise to EBITDA
-11.41xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-235.98%vs Biotechnology peers
Return on Equity (TTM)
-986.32%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 27, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-22.66MUSDvs all stocks (USD)
Net Income (TTM)
-22.47MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-12.49MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-3.34MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-19.45MUSDvs all stocks (USD)
Pre-tax Income
-19.36MUSDFY2025 · Dec 31, 2025Net Income
-19.36MUSDFY2025 · Dec 31, 2025EBIT
-19.45MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-19.45MUSDFY2025 · Dec 31, 2025Research & Development
17.22MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
2.23MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
89.70KUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.43USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.43USDFY2025 · Dec 31, 2025Basic Shares Outstanding
13.53MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
13.53MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-19.36MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-10.11MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
6.18MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-19.36MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.78KUSDFY2025 · Dec 31, 2025Stock-based Compensation
6.80MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.07MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
367.54KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
11.85MUSDFY2025 · Dec 31, 2025Shares Outstanding
14.68MSharesUpdated Sep 27, 2026Float Shares
7.65MSharesUpdated Sep 27, 2026Shares Short
1.63MSharesUpdated Sep 27, 2026Short Ratio
14.01daysvs all stocks
Short % of Shares Outstanding
21.31%vs all stocks
% Held by Insiders
47.91%vs all stocks
% Held by Institutions
12.25%vs all stocks
Total Cash (MRQ)
8.88MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.6050USDUpdated Sep 27, 2026Total Debt (MRQ)
0.00USDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
1.54xvs Biotechnology peers
Book Value per Share (MRQ)
0.2120USDUpdated Sep 27, 2026Total Assets
6.18MUSDvs all stocks (USD)
Total Current Assets
6.18MUSDFY2025 · Dec 31, 2025Total Liabilities
5.82MUSDFY2025 · Dec 31, 2025Total Non-current Assets
0.00USDFY2025 · Dec 31, 2025Total Non-current Liabilities
0.00USDFY2025 · Dec 31, 2025Total Current Liabilities
5.82MUSDFY2025 · Dec 31, 2025Cash
6.18MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
6.18MUSDFY2025 · Dec 31, 2025Accounts Payable
4.87MUSDFY2025 · Dec 31, 2025Deferred Revenue
673.82KUSDFY2025 · Dec 31, 2025Common Stock (Book)
14.30KUSDFY2025 · Dec 31, 2025Retained Earnings
-87.14MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
353.22KUSDvs all stocks (USD)
52-Week Low
7.78USDUpdated Sep 27, 202652-Week High
34.10USDUpdated Sep 27, 202652-Week Change
79.33%vs all stocks
Beta
1.46xvs all stocks
50-Day MA
15.85USDUpdated Sep 27, 2026200-Day MA
21.72USDUpdated Sep 27, 2026Avg 10-Day Volume
144.27KSharesUpdated Sep 27, 2026Avg 30-Day Volume
126.84KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-1.59USDUpdated Sep 27, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -986.3%, lower than 95% of its Biotechnology peers (median -22.3%)Significant
Return on equity: -9.86Industry median: -0.22Industry P5: -1.57Peers compared: 260
Return on assets is -236%, lower than 95% of its Biotechnology peers (median -20.1%)Significant
Return on assets: -2.36Industry median: -0.20Industry P5: -0.83Peers compared: 260
Price-to-book is 85.94×, higher than 95% of its Biotechnology peers (median 2.86×)Significant
Price-to-book: 85.94Industry median: 2.86Industry P95: 13.08Peers compared: 260
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)Notable
Debt-to-equity: 0.00Industry median: 0.07Industry P5: 0.00Peers compared: 260
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 1.54Altman Z-Score: -2.52
Financial Health
Altman Z-Score -2.52: distress zoneCritical
Altman Z-Score: -2.52
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $267.44M, lower than 95% of all stocks globallySignificant
Market cap (USD): 267,436,949Global P5: 275,556,405.438
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
TriSalus Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ginwa Enterprise Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Nucien Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sutro Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Lexeo Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Northwest Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Oryzon Genomics S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Lineage Cell Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tanvex Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cresco Labs Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule